
Labcorp has unveiled a groundbreaking blood test designed to detect early signs of Alzheimer's disease. The Amyloid-Tau-Neurodegeneration (ATN) Profile, comprising three blood biomarkers, significantly advances Alzheimer's diagnosis. While not definitive, it aids doctors in identifying patients requiring advanced testing. Alzheimer's, marked by brain protein buildup, currently demands invasive procedures for diagnosis. Labcorp's test, priced at $626, may streamline the process, potentially allowing timely interventions. Labcorp is in discussions with insurers, but FDA regulations might affect its future. The test's implications for Alzheimer's diagnosis and treatment are promising, heralding a new era in neurodegenerative disease detection.
Like
Save
Share